Read our latest blog from Sarah Fleming, PharmD. – Senior Pharmacy Benefit Clinical Consultant at EPIC Pharmacy Solutions, powered by PSG – for a comprehensive look at GLP-1 drug strategy considerations: https://lnkd.in/gh_d5Gj7 BONUS! 🏆 Download your copy of GLP-1s: 2024 Trends in Drug Benefit Design Report Findings from the form on the blog page to learn about your peers’ experience navigating the GLP-1 landscape. #EmployeeBenefits #BenefitsCurve #PharmacyStrategy #GLP1 #Obesity #Type2Diabetes
EPIC Insurance Brokers & Consultants’ Post
More Relevant Posts
-
Problem solver consistently called upon to define, innovate, and deploy solutions using evidence, analytics, and sales / marketing savvy to generate significant revenues and drive profitability
CMS draft guidance on DPNP could have real implication and overlap with plan sponsor P&T review. Working alongside with Bob Nordyke, we submitted a letter encouraging CMS to provide more clarity and transparency. #Petauri #CMS #ManagedMarkets #MarketAccess
Per CMS, Part D plan sponsors are tasked with making formulary management decisions that are “based on scientific evidence, and may also be based on pharmacoeconomic considerations that achieve appropriate, safe, and cost-effective drug therapy.” Yet, there is no clarity in the Draft Guidance that the analyses CMS is undertaking for the DPNP are grounded in reproducible practices that could be made consistent with plan sponsor assessments or their decisions. We therefore provide several suggestions to improve clarity in the DPNP price-setting and negotiation processes. By not considering the multiple benefits of selected drugs in a manner that is transparent to all stakeholders, especially Part D plan sponsors, there is a high potential for disruptions to patient access to selected drugs. Although our recommendations cannot address some of the fundamental flaws of the IRA, they aim to improve CMS’s ongoing implementation of the law as expectations for transparency and consistency will increase post-Chevron. We encourage you to read our letter here https://lnkd.in/gX7zaq-v and contact us at https://lnkd.in/ebCSBH8b to discuss our comments further. #Healthcare #MarketAccess #CMS
-
-
Per CMS, Part D plan sponsors are tasked with making formulary management decisions that are “based on scientific evidence, and may also be based on pharmacoeconomic considerations that achieve appropriate, safe, and cost-effective drug therapy.” Yet, there is no clarity in the Draft Guidance that the analyses CMS is undertaking for the DPNP are grounded in reproducible practices that could be made consistent with plan sponsor assessments or their decisions. We therefore provide several suggestions to improve clarity in the DPNP price-setting and negotiation processes. By not considering the multiple benefits of selected drugs in a manner that is transparent to all stakeholders, especially Part D plan sponsors, there is a high potential for disruptions to patient access to selected drugs. Although our recommendations cannot address some of the fundamental flaws of the IRA, they aim to improve CMS’s ongoing implementation of the law as expectations for transparency and consistency will increase post-Chevron. We encourage you to read our letter here https://lnkd.in/gX7zaq-v and contact us at https://lnkd.in/ebCSBH8b to discuss our comments further. #Healthcare #MarketAccess #CMS
-
-
The latest episode of Pharmacy Friends “Get the Skinny on GLP-1s” is available to listen to NOW!🎙️ In this episode, industry experts discuss clinical evidence, drug information and appropriate patient selection for GLP1 use. Listen here ➡️ https://lnkd.in/gJ7dwjxb
-
-
Stop paying for assumptions and start paying for reality with CTRx™. Our innovative solution combines prescription services, global pharmacy dispensing, and centralized local drug supply. CTRx ensures your study only uses the drug needed based on patient enrollment, ultimately eliminating drug waste and bulk supply. Transform your drug supply strategy with CTRx. https://bit.ly/3AdqwRt #ClinicalTrials #DrugSupply #EliminateWaste
-
-
Ever wondered how #pharmacy pricing works? 🤔 Our experts Bradley Nelson, PharmD, and Tom Davies, PharmD, break down the complex world of drug pricing, from manufacturer to pharmacy, in the upcoming #Pharmland episode. They unpack terms like WAC, MAC, and AWP – and show how these numbers impact your pharmacy benefits strategy. 💊💡 Want to be the first to know when it drops? Subscribe now and catch up on our previous episodes: https://rxbene.fit/3XLo91o
-
-
Did you get your fill of #pharmacy news this week? Take the #RxRoundup quiz of the week and test your knowledge about the latest stories published by the Drug Topics team from March 4 to March 8. https://lnkd.in/eRwgyvc2 #PharmacyNews #QuizOfTheWeek #QuizOfTheDay #PharmacyNews #HealthcareNews
-
The new edition of the 𝗙𝗟𝗢𝗥𝘅𝗜𝗗𝗔 𝗧𝗶𝗺𝗲𝘀 quarterly newsletter is now available!🌟 Read it at 👉 https://lnkd.in/ggvPWcE8 Stay informed on what is happening around FSHP, including a Clinical Pearl, Member Spotlight, Regional and Component Updates, and more. #FLORxIDAtimes #pharmacy
-
The new edition of the 𝗙𝗟𝗢𝗥𝘅𝗜𝗗𝗔 𝗧𝗶𝗺𝗲𝘀 quarterly newsletter is now available!🌟 Read it at 👉 https://lnkd.in/gd2PVc4M Stay informed on what is happening around FSHP, including a Clinical Pearl, Member Spotlight, Regional and Component Updates, and more. #FLORxIDAtimes #pharmacy
-
-
Curious on how drug pricing works? Listen to this podcast .
Ever wondered how #pharmacy pricing works? 🤔 Our experts Bradley Nelson, PharmD, and Tom Davies, PharmD, break down the complex world of drug pricing, from manufacturer to pharmacy, in the upcoming #Pharmland episode. They unpack terms like WAC, MAC, and AWP – and show how these numbers impact your pharmacy benefits strategy. 💊💡 Want to be the first to know when it drops? Subscribe now and catch up on our previous episodes: https://rxbene.fit/3XLo91o
-
-
Joins us for the latest hot topic!!
Chief Pharmacy Officer RxBenefits, Inc. | President & CEO Innoviant | Director of Pharmacy at Wausau Insurance Companies
Curious about the buzz around GLP-1 medications? Join hosts Bradley Nelson and Tom Davies on Pharmland as they delve into this phenomenon with RxBenefits clinical pharmacist Langley Kyle, PharmD. From marketing tactics to safety concerns, they dissect the factors fueling the rise in GLP-1 usage and examine if these medications live up to the hype. Tune in for an insightful discussion. #Pharmacy #GLP1 #Trends
Pharmland Podcast | RxBenefits
rxbenefits.com
